The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2024

Filed:

Nov. 22, 2018
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Université Paul Sabatier Toulouse Iii, Toulouse, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Inventors:

Julie Guillermet-Guibert, Toulouse, FR;

Thibaut Douche, Toulouse, FR;

Emmanuelle Mouton-Barbosa, Toulouse, FR;

Odile Schiltz, Toulouse, FR;

Marie-Pierre Bousquet, Toulouse, FR;

Célia Cintas, Toulouse, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/32 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57438 (2013.01); C07K 16/303 (2013.01); C07K 16/32 (2013.01); A61K 45/06 (2013.01); C07K 7/08 (2013.01);
Abstract

PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110α and/or p110γ inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.


Find Patent Forward Citations

Loading…